McKesson

MCK · Health Care · Market cap $104B

Q3 FY26 Oct 1 – Dec 31, 2025 reported Feb 4, 2026

Revenue$106.2B +11% year over year

Gross profit$3.7B

Operating profit$1.6B

Net profit$1.2B 1% margin

Numbers and detail

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	106.2	100%	+11%
North American Pharmaceutical	88.3	83%
Oncology & Multispecialty	13	12%
Medical-Surgical Solutions	3	3%	+1%
Prescription Technology	1.5	1%	+9%
Other	0.3	0%
Cost of revenue	−102.5	97%
Gross profit	3.7	3% margin	+0pp
SG&A	−2.1	2%	+0pp
Operating profit	1.6	2% margin	+0pp
Tax	−0.3
Interest & other costs	−0.1
Net profit	1.2	1%	+0pp

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	103.2	100%	+10%
North American Pharmaceutical	86.5	84%
Oncology & Multispecialty	12	12%
Medical-Surgical Solutions	2.9	3%	+0%
Prescription Technology	1.4	1%	+9%
Other	0.3	0%
Cost of revenue	−99.6	97%
Gross profit	3.5	3% margin	+0pp
SG&A	−2.1	2%	−1pp
Operating profit	1.4	1% margin	+1pp
Tax	−0.2
Interest & other costs	−0.1
Net profit	1.1	1%	+1pp

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	97.8	100%	+23%
U.S. Pharmaceutical	90	92%	+34%
International	3.7	4%	+8%
Medical-Surgical Solutions	2.7	3%	+3%
Prescription Technology	1.4	1%	+15%
Cost of revenue	−94.5	97%
Gross profit	3.3	3% margin	−1pp
SG&A	−2.2	2%	+0pp
Operating profit	1	1% margin	+0pp
Tax	−0.2
Net profit	0.8	1%	+0pp

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Dec 31, 2024).
Item	Value	Share of revenue	Year over year
Revenue	95.3	100%	+18%
U.S. Pharmaceutical	87.1	91%
International	3.9	4%
Medical-Surgical Solutions	2.9	3%
Prescription Technology	1.4	1%
Cost of revenue	−92	97%
Gross profit	3.3	3% margin	+0pp
SG&A	−2.1	2%	−1pp
Operating profit	1.2	1% margin	+0pp
Tax	−0.3
Net profit	0.9	1%	+0pp

Quarter by quarter

Pick a quarter and the diagram above changes. Bars compare revenue across the quarters we hold.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q3 FY26	Oct 1 – Dec 31, 2025	Feb 4, 2026	$106.2B	+11%	2%	$1.2B	1%
Q2 FY26	Jul 1 – Sep 30, 2025	Nov 6, 2025	$103.2B	+10%	1%	$1.1B	1%
Q1 FY26	Apr 1 – Jun 30, 2025	Aug 6, 2025	$97.8B	+23%	1%	$0.8B	1%
Q3 FY25	Oct 1 – Dec 31, 2024	Feb 6, 2025	$95.3B	+18%	1%	$0.9B	1%